AR068669A1 - Metodo para aliviar la queratoconjuntivitis seca - Google Patents
Metodo para aliviar la queratoconjuntivitis secaInfo
- Publication number
- AR068669A1 AR068669A1 ARP080104346A ARP080104346A AR068669A1 AR 068669 A1 AR068669 A1 AR 068669A1 AR P080104346 A ARP080104346 A AR P080104346A AR P080104346 A ARP080104346 A AR P080104346A AR 068669 A1 AR068669 A1 AR 068669A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- topical
- salts
- group
- civamide
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000003444 anaesthetic effect Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940125379 topical corticosteroid Drugs 0.000 abstract 3
- 230000000699 topical effect Effects 0.000 abstract 3
- 229960002504 capsaicin Drugs 0.000 abstract 2
- 235000017663 capsaicin Nutrition 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 abstract 2
- 229960002860 zucapsaicin Drugs 0.000 abstract 2
- 206010006784 Burning sensation Diseases 0.000 abstract 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract 1
- 229960002537 betamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract 1
- -1 capsaicinoid compound Chemical class 0.000 abstract 1
- 229960001747 cinchocaine Drugs 0.000 abstract 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 201000010666 keratoconjunctivitis Diseases 0.000 abstract 1
- 229960004194 lidocaine Drugs 0.000 abstract 1
- 210000002850 nasal mucosa Anatomy 0.000 abstract 1
- 229960001896 pramocaine Drugs 0.000 abstract 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001807 prilocaine Drugs 0.000 abstract 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La incorporacion opcional a la formulacion intranasal de un corticosteroide topico o un compuesto anestésico topico se usa para reducir la sensacion punzante o quemante transitoria que en ocasiones acompana la administracion intranasal de capsaicinoides. Reivindicacion 1: Un método para tratar queratoconjuntivitis seca mediante la administracion de una cantidad efectiva de una composicion, caracterizado porque comprende compuestos capsaicinoides, adecuados para la administracion intranasal sobre la mucosa nasal. Reivindicacion 2: El método de acuerdo con la reivindicacion 1 caracterizado porque dicho compuesto capsaicinoide se selecciona de! grupo que consiste de capsaicina, civamida, compuestos acetilados de capsaicina y civamida, y las sales de todos los capsaicinoides antes mencionados. Reivindicacion 5: El método de acuerdo con la reivindicacion 2, caracterizado porque además comprende un anestésico topico o un corticosteroide topico. Reivindicacion 6: El método de acuerdo con la reivindicacion 5, caracterizado porque dicho anestésico topico se selecciona del grupo que incluye pramoxina, lidocaína, dibucaína, prilocaína, sus sales y compuestos de esencialmente la misma funcion. Reivindicacion 8: El método de acuerdo con la reivindicacion 5, caracterizado porque dicho corticosteroide topico se selecciona de un grupo que incluye hidrocortisona, triamcinolona, betametasona, sus sales o compuestos relacionados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/868,286 US20090093446A1 (en) | 2007-10-05 | 2007-10-05 | Method for alleviating keratoconjunctivitis sicca |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068669A1 true AR068669A1 (es) | 2009-11-25 |
Family
ID=40523784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104346A AR068669A1 (es) | 2007-10-05 | 2008-10-03 | Metodo para aliviar la queratoconjuntivitis seca |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090093446A1 (es) |
| EP (1) | EP2094256A4 (es) |
| JP (1) | JP2009545634A (es) |
| KR (1) | KR20090080017A (es) |
| CN (1) | CN101616663A (es) |
| AR (1) | AR068669A1 (es) |
| AU (1) | AU2007349197A1 (es) |
| BR (1) | BRPI0710595A2 (es) |
| CA (1) | CA2644733A1 (es) |
| IL (1) | IL198657A0 (es) |
| MX (1) | MX2008013039A (es) |
| NZ (1) | NZ571467A (es) |
| WO (1) | WO2009045224A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166925B2 (en) | 2018-08-23 | 2021-11-09 | Elorac, Inc. | Method for alleviating keratoconjunctivitis sicca |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019203A2 (en) * | 2010-08-03 | 2012-02-09 | Dynova Laboratories, Inc. | Therapeutic agent for intranasal administration and method of making and using same |
| WO2012068247A1 (en) | 2010-11-16 | 2012-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treatment of dry eye |
| US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
| AU2012279499B2 (en) * | 2011-07-07 | 2017-05-04 | Eva MILLQVIST | Cough reducing product |
| WO2014031964A1 (en) * | 2012-08-24 | 2014-02-27 | Vr1, Inc. | Composition for the treatment of migraine headaches |
| WO2014172693A2 (en) | 2013-04-19 | 2014-10-23 | Oculeve, Inc. | Nasal stimulation devices and methods |
| BR112017008097B1 (pt) | 2014-10-20 | 2023-03-28 | Oyster Point Pharma, Inc | Método para tratar condições oculares |
| MX2017005204A (es) * | 2014-10-22 | 2017-12-14 | Oculeve Inc | Dispositivos y métodos de estimulación para tratar el ojo seco. |
| DK3439661T3 (da) | 2016-04-07 | 2021-10-18 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
| WO2017192572A1 (en) | 2016-05-02 | 2017-11-09 | Oculeve, Inc. | Intranasal stimulation for treatment of meibomian gland disease and blepharitis |
| WO2020014217A1 (en) * | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| KR20210021017A (ko) * | 2018-08-23 | 2021-02-24 | 엘로락, 인크. | 건성각결막염을 경감시키기 위한 방법 및 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5134166A (en) * | 1988-12-02 | 1992-07-28 | Genderm Corporation | Method for treating nasal disorders and headaches |
| CA2017383A1 (en) * | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Use of vanilloids for the treatment of respiratory diseases or disorders |
| US5063060A (en) * | 1989-12-19 | 1991-11-05 | Cisco Limited Partnership | Compositions and method for treating painful, inflammatory or allergic disorders |
| DE59408028D1 (de) * | 1993-09-30 | 1999-05-06 | Medichemie Ag | Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie |
| CH690023A5 (de) * | 1996-02-02 | 2000-03-31 | Medichemie Ag | Mittel zur Behandlung krankhafter Zellveränderungen der Nasenschleimhaut. |
| EP1004307B1 (en) * | 1998-01-30 | 2002-09-04 | R-Tech Ueno, Ltd. | Ophthalmic composition |
| JP4653516B2 (ja) * | 2004-02-27 | 2011-03-16 | 扶桑薬品工業株式会社 | 涙液分泌促進ペプチドおよびその組成物 |
| DE102004063363A1 (de) * | 2004-06-28 | 2006-01-19 | Weber, Erhard, Dr. | Capsaicin-haltige Arzneien zur Behandlung von Bronchial-Infekten und Allergien |
| CN101119713A (zh) * | 2004-11-24 | 2008-02-06 | 阿尔高克斯制药公司 | 类辣椒素凝胶制剂及其用途 |
-
2007
- 2007-10-05 US US11/868,286 patent/US20090093446A1/en not_active Abandoned
- 2007-10-08 KR KR1020087027865A patent/KR20090080017A/ko not_active Ceased
- 2007-10-08 WO PCT/US2007/080707 patent/WO2009045224A1/en not_active Ceased
- 2007-10-08 MX MX2008013039A patent/MX2008013039A/es not_active Application Discontinuation
- 2007-10-08 EP EP07868388A patent/EP2094256A4/en not_active Withdrawn
- 2007-10-08 CN CN200780013856A patent/CN101616663A/zh active Pending
- 2007-10-08 JP JP2009536368A patent/JP2009545634A/ja active Pending
- 2007-10-08 BR BRPI0710595-9A patent/BRPI0710595A2/pt not_active IP Right Cessation
- 2007-10-08 AU AU2007349197A patent/AU2007349197A1/en not_active Abandoned
- 2007-10-08 NZ NZ571467A patent/NZ571467A/en unknown
- 2007-10-08 CA CA002644733A patent/CA2644733A1/en not_active Abandoned
-
2008
- 2008-10-03 AR ARP080104346A patent/AR068669A1/es unknown
-
2009
- 2009-05-07 IL IL198657A patent/IL198657A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166925B2 (en) | 2018-08-23 | 2021-11-09 | Elorac, Inc. | Method for alleviating keratoconjunctivitis sicca |
| US11478439B2 (en) | 2018-08-23 | 2022-10-25 | Elorac, Inc. | Method for alleviating keratoconjunctivitis sicca |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009545634A (ja) | 2009-12-24 |
| IL198657A0 (en) | 2010-02-17 |
| KR20090080017A (ko) | 2009-07-23 |
| AU2007349197A1 (en) | 2009-04-23 |
| NZ571467A (en) | 2009-03-31 |
| WO2009045224A1 (en) | 2009-04-09 |
| EP2094256A4 (en) | 2009-11-11 |
| EP2094256A1 (en) | 2009-09-02 |
| BRPI0710595A2 (pt) | 2011-08-16 |
| MX2008013039A (es) | 2009-06-05 |
| CA2644733A1 (en) | 2009-04-05 |
| US20090093446A1 (en) | 2009-04-09 |
| CN101616663A (zh) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068669A1 (es) | Metodo para aliviar la queratoconjuntivitis seca | |
| BRPI0820171B8 (pt) | compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos | |
| AR064077A1 (es) | Composiciones bajo forma de unguento sin vaselina que comprende un derivado de vitamina d y eventualmente un anti-inflamatorio esteroide | |
| JP2014527964A5 (es) | ||
| AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
| ECSP109917A (es) | Nuevos derivados de ácido azabifenilaminobenzoico | |
| CL2007003491A1 (es) | Forma cristalina del acido (3s)-3-[n-(n-(2-tercbutilfenil)oxamil)alaninil]amino-5(23,5,6-tetrafluorofenoxi)-4-oxopentanoico; composicion farmaceutica que comprende a dicho compuesto; y su uso para tratar la fibrosis hepatica. | |
| CO6321221A2 (es) | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal | |
| CU20100238A7 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato | |
| CO6410279A2 (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| MX2020005841A (es) | Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| CR10782A (es) | Compuestos para inhibir la progresion mitotica | |
| MX2016008594A (es) | Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol. | |
| CL2008003096A1 (es) | Compuestos derivados de piperidino-dihidrotienopirimidinas; inhibidores pde4; composicion farmaceutica que los comprende; y uso en el tratamiento de trastornos o enfermedades de las vias respiratorias o gastrointestinales, como tambien enfermedades inflamatorias de las articulaciones u ojos, entre otras. | |
| CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
| SV2009002903A (es) | Compuestos para la inhibicion de enzimas | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| EA201071235A1 (ru) | Жидкая композиция для деферипрона с приятным вкусом | |
| UY31922A (es) | Compuestos | |
| ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
| CL2004000848A1 (es) | Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras | |
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| BR112015023761A2 (pt) | moduladores de molécula pequena de pcsk9 e seus métodos e usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |